The fusion of exon 1 of the CTRC1 gene on chromosome 19p13 with exons 2–5 of the MAML2 gene on chromosome 11q21 generates a novel fusion oncogene, CRTC1-MAML2, that acts as a transcription factor altering Notch and CREB regulatory pathways, leading to disruption of normal cellular growth and differentiation that contributes to tumor development [29, 30]. This evidence concerns the gene CRTC1 and neoplasm.